InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
0.00%
)
US TECH 100
19,172.40
(
0.03%
)
Dow Jones
38,589.16
(
0.00%
)
Brent Oil
82.50
(
0.45%
)
Bitcoin
65,512.01
(
-1.69%
)
Post# of 177
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

surf1944

Send PM Follow Ignore
Followers 467
Posts 26931
Boards Moderated 2
Alias Born 09/11/2006

surf1944

Re: None

Tuesday, 05/04/2010 9:35:36 AM

Tuesday, May 04, 2010 9:35:36 AM

Post# of 177
7:06AM Pharmasset announces results of a 28-day phase 2a study with PSI-7977 for the treatment of chronic hepatitis C infection (VRUS) 32.74 : Co announced today the preliminary safety results from its 28 day phase 2a study with PSI-7977 dosed once daily combhined with Pegasys and Copegus. PSI-7977 demonstrated potent short term antiviral activity and was generally safe and well tolerated. All patients receiving active PSI-7977 demonstrated continuous and substantial declines in HCV RNA with no viral breakthrough during 28 days of therapy at any dose.


surf's up......crikey



Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up